NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price & News

$18.50

-0.20 (-1.07%)

(As of 04:23 PM ET)

Compare

Today's Range: $17.83
▼
$18.66
50-Day Range: $18.08
▼
$23.45
52-Week Range: $17.80
▼
$41.93

Volume: 2.07 million shs
Average Volume: 1.03 million shs
Market Capitalization: $1.25 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $49.40

Amylyx Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 166.2% Upside
$49.40 Price Target
Short Interest: Bearish
19.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 164.66%
From $1.16 to $3.07 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

150th out of 975 stocks

Pharmaceutical Preparations Industry

53rd out of 456 stocks

3.5

Analyst's Opinion

Consensus Rating
Amylyx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $49.40, Amylyx Pharmaceuticals has a forecasted upside of 166.2% from its current price of $18.56.
Amount of Analyst Coverage
Amylyx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
19.10% of the float of Amylyx Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.
Change versus previous month
Short interest in Amylyx Pharmaceuticals has recently increased by 4.20%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Amylyx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Amylyx Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMLX.

3.0

News and Social Media Coverage

News Sentiment
Amylyx Pharmaceuticals has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Amylyx Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.
MarketBeat Follows
7 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amylyx Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.80% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
87.70% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Amylyx Pharmaceuticals are expected to grow by 164.66% in the coming year, from $1.16 to $3.07 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amylyx Pharmaceuticals is -14.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amylyx Pharmaceuticals is -14.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Amylyx Pharmaceuticals has a PEG Ratio of 0.25. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Amylyx Pharmaceuticals has a P/B Ratio of 3.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

AMLX Price History

30 days | 90 days | 365 days | Advanced Chart

AMLX Stock News Headlines

September 20, 2023 | finance.yahoo.com

Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?

September 11, 2023 | seekingalpha.com

Amylyx Pharmaceuticals: A High Risk/High Reward Stock

September 28, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 22, 2023 | finance.yahoo.com

The past year for Amylyx Pharmaceuticals (NASDAQ:AMLX) investors has not been profitable

August 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Galecto (GLTO), Amylyx Pharmaceuticals Inc (AMLX)

August 14, 2023 | finance.yahoo.com

Amylyx's new ALS drug has turned a profit for six months straight

August 13, 2023 | finance.yahoo.com

AMLX - Amylyx Pharmaceuticals, Inc.

August 13, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2023 Earnings Call Transcript

September 28, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 11, 2023 | finance.yahoo.com

Q2 2023 Amylyx Pharmaceuticals Inc Earnings Call

August 11, 2023 | seekingalpha.com

Amylyx Achieves Profitability On Wings Of Relyvrio (Rating Upgrade)

August 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioNTech SE (BNTX) and Bright Health Group (BHG)

August 11, 2023 | seekingalpha.com

Amylyx Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 11, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results

August 3, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023

July 28, 2023 | markets.businessinsider.com

Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from Mizuho Securities

July 28, 2023 | finance.yahoo.com

Goldman Sachs Predicts up to 120% Rally for These 2 Stocks — Here’s Why They Have Solid Upside

July 27, 2023 | markets.businessinsider.com

Bank of America Securities Sticks to Its Buy Rating for Amylyx Pharmaceuticals Inc (AMLX)

July 24, 2023 | markets.businessinsider.com

Amylyx Stock Has A Good Entry Point, Says Bullish Goldman Sachs

July 24, 2023 | finance.yahoo.com

Why Shares of Amylyx Pharmaceuticals Were Up Monday

July 18, 2023 | finance.yahoo.com

3 Stocks Worth a Buy for Remarkable Earnings Acceleration

July 12, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program

June 26, 2023 | markets.businessinsider.com

Mizuho Securities Sticks to Their Buy Rating for Amylyx Pharmaceuticals Inc (AMLX)

June 23, 2023 | msn.com

EMA panel gives negative opinion on Amylix ALS drug application

June 23, 2023 | markets.businessinsider.com

Amylyx Pharma: CHMP Adopts Negative Opinion On Conditional Marketing Authorisation Of AMX0035

June 23, 2023 | markets.businessinsider.com

EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's Amyotrophic Lateral Sclerosis Treatment

June 23, 2023 | finance.yahoo.com

Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

See More Headlines

Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Company Calendar

Last Earnings: 8/10/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AMLX
CUSIP: N/A
CIK: 1658551
Web: amylyx.com
Phone: 617-682-0917
Fax: N/A
Employees: 338
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $49.40
High Stock Price Forecast: $50.00
Low Stock Price Forecast: $48.00
Forecasted Upside/Downside: +167.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 15.95
P/E Growth: 0.25
Net Income: $-198,380,000.00
Net Margins: -37.95%
Pretax Margin: -36.79%
Return on Equity: -23.80%
Return on Assets: -20.30%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.67
Quick Ratio: 6.28

Sales & Book Value

Annual Sales: $22.23 million
Price / Sales: 56.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.14 per share
Price / Book: 3.60

Miscellaneous

Outstanding Shares: 67,380,000
Free Float: 59,427,000
Market Cap: $1.25 billion
Optionable: Not Optionable
Beta: -0.93

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Joshua B. Cohen (Age 31)
Co-Founder, Co-CEO & Director
Comp: $1M

Mr. Justin B. Klee (Age 32)
Co-Founder, Co-CEO & Director
Comp: $1M

Mr. James M. Frates M.B.A. (Age 56)
Chief Financial Officer
Comp: $695.12k

Ms. Gina M. Mazzariello (Age 52)
Chief Legal Officer & Gen. Counsel
Comp: $794.83k

Mr. Tom Holmes
Chief Technical Operations Officer

Lindsey Allen
Head of Investor Relations & Communications

Ms. Shauna Horvath
Head of Global Marketing

Ms. Debra L. Canner (Age 64)
Global Head of HR & CHRO

Ms. Margaret M. Olinger M.B.A (Age 58)
Global Head of Commercial & Chief Commercial Officer

Dr. Patrick D. Yeramian M.D. (Age 64)
MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMLX Stock - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMLX shares.
View AMLX analyst ratings or view top-rated stocks.
What is Amylyx Pharmaceuticals' stock price forecast for 2023?: 5 equities research analysts have issued 1 year price objectives for Amylyx Pharmaceuticals' stock. Their AMLX share price forecasts range from $48.00 to $50.00. On average, they anticipate the company's share price to reach $49.40 in the next year. This suggests a possible upside of 167.0% from the stock's current price.
View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts.
How have AMLX shares performed in 2023?: Amylyx Pharmaceuticals' stock was trading at $36.95 at the beginning of the year. Since then, AMLX shares have decreased by 49.9% and is now trading at $18.50.
View the best growth stocks for 2023 here.
When is Amylyx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our AMLX earnings forecast.
How were Amylyx Pharmaceuticals' earnings last quarter?: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced its quarterly earnings data on Thursday, August, 10th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.30. The firm had revenue of $98.22 million for the quarter, compared to analysts' expectations of $84.30 million. Amylyx Pharmaceuticals had a negative trailing twelve-month return on equity of 23.80% and a negative net margin of 37.95%.
What ETFs hold Amylyx Pharmaceuticals' stock?: ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE).

When did Amylyx Pharmaceuticals IPO?: (AMLX) raised $190 million in an IPO on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.
What is Amylyx Pharmaceuticals' stock symbol?: Amylyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLX."
Who are Amylyx Pharmaceuticals' major shareholders?: Amylyx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (7.23%), BlackRock Inc. (5.22%), Marshall Wace LLP (2.94%), Rock Springs Capital Management LP (2.29%), Goldman Sachs Group Inc. (2.00%) and State Street Corp (1.72%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian.
View institutional ownership trends.
How do I buy shares of Amylyx Pharmaceuticals?: Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Amylyx Pharmaceuticals' stock price today?: One share of AMLX stock can currently be purchased for approximately $18.50.
How much money does Amylyx Pharmaceuticals make?: Amylyx Pharmaceuticals (NASDAQ:AMLX) has a market capitalization of $1.25 billion and generates $22.23 million in revenue each year. The company earns $-198,380,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.
How many employees does Amylyx Pharmaceuticals have?: The company employs 338 workers across the globe.
How can I contact Amylyx Pharmaceuticals?: The official website for the company is amylyx.com. The company can be reached via phone at 617-682-0917 or via email at investors@amylyx.com.

This page (NASDAQ:AMLX) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial